NIFTY 5023162 0.23%BANKNIFTY55177 0.14%SENSEX73833 0.20%FTSE 10010357 0.99%EURO STOXX 506075.42 1.09%DAX24257 0.25%CAC 408241.41 0.97%NIKKEI 22564217 0.06%KOSPI7763.95 0.43%SSE COMP3987.01 0.16%S&P 5007266.99 1.62%NASDAQ25170 1.98%DOW JONES49919 1.87%Gold4095.90 0.30%Silver63.750 1.31%Crude Oil (WTI)89.050 1.09%Crude Oil (Brent)91.940 1.25%NIFTY 5023162 0.23%BANKNIFTY55177 0.14%SENSEX73833 0.20%FTSE 10010357 0.99%EURO STOXX 506075.42 1.09%DAX24257 0.25%CAC 408241.41 0.97%NIKKEI 22564217 0.06%KOSPI7763.95 0.43%SSE COMP3987.01 0.16%S&P 5007266.99 1.62%NASDAQ25170 1.98%DOW JONES49919 1.87%Gold4095.90 0.30%Silver63.750 1.31%Crude Oil (WTI)89.050 1.09%Crude Oil (Brent)91.940 1.25%
marketkin
← Back to News
🇬🇧June 9, 2026

Beauty Pie LED mask ad banned over misleading anti-wrinkle claim

The UK advertising watchdog has banned Beauty Pie's LED mask advertisement after determining the product was not clinically proven to reduce wrinkles in four weeks as claimed. The ruling highlights regulatory scrutiny of beauty and personal care product marketing claims in the United Kingdom.

Beauty Pie's LED mask advertisement has been prohibited by the UK advertising watchdog following a determination that the company's central marketing claim was unsubstantiated. According to the watchdog's findings, the mask is not clinically proven to reduce wrinkles in the stated four-week timeframe, contradicting the assertion made in the advertisement. The regulatory action indicates that Beauty Pie failed to provide adequate clinical evidence to support its anti-wrinkle efficacy claims before running the campaign.

This enforcement action reflects the broader regulatory environment governing beauty and personal care product advertising in the United Kingdom. Advertising watchdogs in major markets increasingly scrutinize health and efficacy claims in the cosmetics sector, particularly those suggesting rapid or clinically proven results. Companies marketing skincare devices and beauty products must substantiate performance claims with robust clinical data before disseminating advertisements to consumers. The ruling serves as a reminder to the industry that unverified claims—especially those suggesting specific timelines for visible results—face heightened regulatory risk. For market participants in the beauty technology and skincare sectors, such decisions underscore the importance of investing in clinical validation studies and maintaining detailed documentation of product efficacy. Regulatory compliance costs and potential reputational damage from advertising bans can significantly impact brand positioning and consumer trust in the competitive beauty market.

Source: BBC News

This article is an editorial summary sourced from third-party news providers and is produced by marketkin.com for informational purposes only. It does not constitute investment advice. Disclaimer